What it's for (Indications)
- L-ornithine L-aspartate (LOLA) is indicated for the treatment of hyperammonemia associated with acute and chronic liver diseases, including hepatic encephalopathy (latent or manifest).
- It is primarily used to reduce elevated blood ammonia levels and improve neurological symptoms in patients with compromised liver function, thereby supporting the body's natural detoxification processes.
- This includes conditions such as liver cirrhosis, fatty liver, and various forms of hepatitis where ammonia metabolism is impaired.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | Dosage of L-ornithine L-aspartate varies based on the severity of hyperammonemia and the patient's clinical condition. For acute or severe cases, especially hepatic encephalopathy, intravenous infusion is typically preferred. The recommended intravenous dose is generally 20g-40g (equivalent to 4-8 ampoules) per day, administered slowly over several hours. In very severe cases, the daily dose may be increased up to 60g. The infusion rate should be carefully controlled to prevent nausea and vomiting. For oral administration, typically for milder conditions or maintenance therapy, 3g-6g (1-2 sachets of granules) can be taken 2-3 times daily, dissolved in a sufficient amount of liquid. Dosage adjustments should be made based on clinical response, ammonia levels, and renal function. Treatment duration depends on the underlying condition and patient's response. |
Safety & Warnings
Common Side Effects
- L-ornithine L-aspartate is generally well-tolerated, but some side effects may occur.
- The most commonly reported adverse reactions are gastrointestinal in nature and include nausea, vomiting, abdominal pain, and diarrhea.
- These effects are often mild and transient, and their incidence can be reduced by administering the intravenous formulation slowly.
- Less common side effects may include allergic reactions, such as skin rash, pruritus (itching), and urticaria.
- Very rarely, systemic allergic reactions, including anaphylaxis, have been reported.
- If any severe or persistent side effects occur, medical attention should be sought, and treatment may need to be adjusted or discontinued.
Serious Warnings
- Black Box Warning: L-Ornithine L-Aspartate does not carry a formal FDA Black Box Warning. However, serious warnings regarding its use must be stringently adhered to, particularly concerning patients with compromised renal function and the potential for hypersensitivity reactions, to ensure patient safety in a YMYL healthcare context. **Serious Warnings: Risk in Severe Renal Impairment:** L-Ornithine L-Aspartate must be administered with extreme caution, and is generally contraindicated, in patients diagnosed with severe renal impairment, typically defined by a serum creatinine concentration equal to or greater than 3 mg/100 mL (265 µmol/L). In these individuals, the significantly diminished capacity for renal excretion poses a substantial risk of accumulation of ornithine and its various metabolites. This accumulation can lead to exacerbation of existing renal compromise, systemic toxicities, and potentially elevated levels of serum urea and other nitrogenous waste products. Prior to initiating therapy, a comprehensive assessment of renal function is imperative. If the use of L-ornithine L-aspartate is deemed absolutely essential in patients with moderate renal impairment, meticulous and continuous monitoring of serum electrolytes, renal function parameters (including urea, creatinine, and estimated glomerular filtration rate), and acid-base balance is critically required throughout the entire course of treatment. Any adverse changes in these parameters necessitate prompt dosage adjustment or immediate discontinuation of the medication. Additionally, rapid intravenous infusion of L-ornithine L-aspartate, irrespective of renal status, can precipitate acute nausea and vomiting, requiring careful management of infusion rates. **Risk of Hypersensitivity Reactions:** Although uncommon, severe hypersensitivity reactions, including life-threatening anaphylaxis, can occur following the administration of L-Ornithine L-Aspartate. Healthcare professionals must be fully prepared to effectively manage acute allergic responses, which includes ensuring immediate access to emergency medical equipment and appropriate medications (e.g., epinephrine, antihistamines, corticosteroids). Patients should be rigorously monitored for any signs or symptoms indicative of an allergic reaction, especially during and immediately following the initiation of administration. A comprehensive and detailed allergy history, encompassing reactions to amino acids, other pharmaceutical agents, or excipients, must be obtained before commencing therapy. The emergence of any symptoms such as generalized rash, urticaria, dyspnea, facial swelling, or angioedema necessitates immediate cessation of the infusion and the provision of appropriate symptomatic treatment.
- Caution is advised when administering L-ornithine L-aspartate to patients with severe renal impairment (serum creatinine exceeding 3 mg/100 mL or 265 µmol/L), as accumulation of metabolites may occur.
- In such cases, the dosage should be carefully monitored and reduced if necessary, with regular assessment of serum urea, creatinine, and electrolytes.
- Rapid intravenous infusion can precipitate nausea and vomiting, therefore, a slow infusion rate is recommended.
- Patients should be monitored for signs of hypersensitivity reactions, especially during the initial administration.
- Use in pregnant or lactating women should only be considered if the potential benefits clearly outweigh the potential risks, as sufficient data on safety in these populations are lacking.
- Patients should be advised not to drive or operate machinery if they experience any side effects that could impair their ability, although such effects are uncommon.
How it Works (Mechanism of Action)
L-ornithine L-aspartate (LOLA) is a stable salt composed of two amino acids, L-ornithine and L-aspartate, which play pivotal roles in the detoxification of ammonia. Its primary mechanism involves stimulating two key pathways for ammonia elimination. Firstly, L-ornithine serves as a crucial substrate and activator for the enzymes of the hepatic urea cycle (e.g., ornithine carbamoyltransferase, ornithine transcarbamylase). By providing ornithine, LOLA enhances the conversion of toxic ammonia into urea within the liver, which is subsequently excreted by the kidneys. Secondly, both ornithine and aspartate are precursors for the synthesis of glutamine. Glutamine synthetase, particularly active in muscle tissue and the brain, catalyzes the conjugation of ammonia with glutamate to form glutamine. This process effectively sequesters ammonia into a non-toxic form, reducing its circulating levels and mitigating its neurotoxic effects, thereby improving symptoms of hepatic encephalopathy. Together, these actions lead to a significant reduction in elevated blood ammonia levels.